Correlation
The correlation between TAK and LLY is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
TAK vs. LLY
Compare and contrast key facts about Takeda Pharmaceutical Company Limited (TAK) and Eli Lilly and Company (LLY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: TAK or LLY.
Performance
TAK vs. LLY - Performance Comparison
Loading data...
Key characteristics
TAK:
0.92
LLY:
-0.23
TAK:
1.27
LLY:
-0.04
TAK:
1.17
LLY:
0.99
TAK:
0.39
LLY:
-0.32
TAK:
3.01
LLY:
-0.59
TAK:
5.75%
LLY:
13.61%
TAK:
19.73%
LLY:
38.49%
TAK:
-52.76%
LLY:
-68.27%
TAK:
-32.59%
LLY:
-22.74%
Fundamentals
TAK:
$46.95B
LLY:
$662.23B
TAK:
$0.23
LLY:
$12.54
TAK:
65.35
LLY:
58.83
TAK:
0.42
LLY:
1.13
TAK:
0.01
LLY:
13.51
TAK:
0.97
LLY:
42.01
TAK:
$3.53T
LLY:
$49.00B
TAK:
$2.02T
LLY:
$40.03B
TAK:
$764.83B
LLY:
$16.27B
Returns By Period
In the year-to-date period, TAK achieves a 13.52% return, which is significantly higher than LLY's -4.09% return. Over the past 10 years, TAK has underperformed LLY with an annualized return of -0.09%, while LLY has yielded a comparatively higher 27.48% annualized return.
TAK
13.52%
-0.00%
10.35%
15.22%
5.09%
-1.38%
-0.09%
LLY
-4.09%
-6.92%
-6.90%
-9.46%
34.17%
38.59%
27.48%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
TAK vs. LLY — Risk-Adjusted Performance Rank
TAK
LLY
TAK vs. LLY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Takeda Pharmaceutical Company Limited (TAK) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
TAK vs. LLY - Dividend Comparison
TAK's dividend yield for the trailing twelve months is around 2.22%, more than LLY's 0.76% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TAK Takeda Pharmaceutical Company Limited | 2.22% | 4.78% | 4.41% | 3.69% | 5.80% | 3.84% | 4.94% | 8.33% | 5.14% | 6.91% | 5.34% | 5.03% |
LLY Eli Lilly and Company | 0.76% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.95% | 2.46% | 2.77% | 2.37% | 2.84% |
Drawdowns
TAK vs. LLY - Drawdown Comparison
The maximum TAK drawdown since its inception was -52.76%, smaller than the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for TAK and LLY.
Loading data...
Volatility
TAK vs. LLY - Volatility Comparison
The current volatility for Takeda Pharmaceutical Company Limited (TAK) is 8.19%, while Eli Lilly and Company (LLY) has a volatility of 16.63%. This indicates that TAK experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
TAK vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Takeda Pharmaceutical Company Limited and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TAK vs. LLY - Profitability Comparison
TAK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Takeda Pharmaceutical Company Limited reported a gross profit of 727.25B and revenue of 1.14T. Therefore, the gross margin over that period was 63.6%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Eli Lilly and Company reported a gross profit of 10.50B and revenue of 12.73B. Therefore, the gross margin over that period was 82.5%.
TAK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Takeda Pharmaceutical Company Limited reported an operating income of -22.45B and revenue of 1.14T, resulting in an operating margin of -2.0%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Eli Lilly and Company reported an operating income of 5.41B and revenue of 12.73B, resulting in an operating margin of 42.5%.
TAK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Takeda Pharmaceutical Company Limited reported a net income of 23.79B and revenue of 1.14T, resulting in a net margin of 2.1%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Eli Lilly and Company reported a net income of 2.76B and revenue of 12.73B, resulting in a net margin of 21.7%.